Esperion Therapeutics, Inc.
ESPR
$2.18
-$0.01-0.46%
NASDAQ
| 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | |
|---|---|---|---|---|---|
| Net Income | 68.55% | -89.77% | 27.79% | 52.32% | -201.48% |
| Total Depreciation and Amortization | 3.85% | -3.70% | 3.85% | 160.00% | -- |
| Total Amortization of Deferred Charges | 17.31% | 306.40% | -61.52% | 1.13% | 1.14% |
| Total Other Non-Cash Items | 33.39% | -32.12% | 21.62% | -89.63% | 318.20% |
| Change in Net Operating Assets | -318.76% | 156.45% | -71.56% | -148.45% | 77.07% |
| Cash from Operations | -38.86% | 35.26% | 1.06% | -390.28% | -113.39% |
| Capital Expenditure | -- | -- | 100.00% | -116.88% | -5.48% |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -- | -- | -- | -- | -- |
| Cash from Investing | -- | -- | 100.00% | -116.88% | -5.48% |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | -- | -- | -- | -94.15% | -90.59% |
| Repurchase of Common Stock | -- | -- | -- | 100.00% | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | 100.00% | -105.16% | 1,610.54% | -103.16% | 5,323.87% |
| Cash from Financing | 138.00% | -121.43% | 484.78% | 69.71% | -133.14% |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 5.16% | -68,572.73% | 100.10% | -19.52% | -125.84% |